Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T17:05:50.189Z Has data issue: false hasContentIssue false
  • English
  • Français

Bromocriptine improves digit symbol substitution test scores in neuroleptic-treated chronic schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

C de Beaurepaire ,
R de Beaurepaire ,
M Cleau  and
Ρ Borenstein
C de Beaurepaire
Affiliation:
CHS de villejuif, 54 avenue de la République, 94800villejuif
R de Beaurepaire
Affiliation:
CHS du Bon-Sauveur, 93, rue Caponière, 14012Caen, France
M Cleau
Affiliation:
CHS de villejuif, 54 avenue de la République, 94800villejuif
Ρ Borenstein
Affiliation:
CHS de villejuif, 54 avenue de la République, 94800villejuif
Get access

Summary

The cognitive effects of bromocriptine (10 mg/day) in chronic neuroleptic-treated schizophrenic patients were studied in a 4-month trial. Ten neuropsychological variables were used for the evaluations. Nine patients and seven controls completed the study. They were tested three times: before the beginning of the study, and after 2 and 4 months of treatment. The results showed that treated patients globally performed significantly better than the controls (P < 0.05), and that the digit symbol substitution test was significantly improved (P < 0.03). The WAIS performance score was also significantly improved (P < 0.02). The picture arrangement test was improved, but did not reach significance (P < 0.07). Verbal tests were not improved. It therefore appears that addition of a D2 dopamine agonist in neuroleptic-treated patients can improve some of their cognitive functions. Two explanations can be proposed: i) bromocriptine decreases neuroleptic-induced motor side effects or ii) has an effect on a putative hypodopaminergic function in schizophrenia.

Keywords

bromocriptinedopamineneurolepticsschizophreniaside-effectsneuropsychology
Type
Origianl article
Information
European Psychiatry , Volume 8 , Issue 2 , 1993 , pp. 89 - 93
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Borenstein, PSoret, CGraille, D (1981) Contribution à l’étude des syndromes démentiels sous l’action de la bromocriptine. Sem Hôp Paris 57, 801–809Google Scholar
Cleghorn, JMKaplan, RDSzechtman, BSzechtman, HBrown, GM (1990) Neuroleptic drug effects on cognitive function in schizophrenia. Schizo Res 3, 211–219CrossRefGoogle Scholar
Cutmore, TRHBeninger, RJ (1990) Do neuroleptics impair learning in schizophrenic patients? Schizo Res 3, 173–186CrossRefGoogle ScholarPubMed
Decker, BLDavis, JMJanowski, DSEl Yoosef, MKSekerke, HJ (1971) Amantadine hypochloride treatment of tardive dyskynesia. N Engl J Med 285, 860Google Scholar
Gattaz, WFRost, WHübner, CKBauer, K (1989) Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. Biol Psychiatry 25, 247–255CrossRefGoogle ScholarPubMed
Gelenberg, AHMande, MR (1977) Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 34, 947–950CrossRefGoogle ScholarPubMed
Goldstein, GHalperin, MM (1977) Neuropsychological differencies among subtypes of schizophrenia. Abnorm Psychol 80, 34–40CrossRefGoogle Scholar
Jackson, DMJenkins, OFRoss, SB (1988) The motor effects of bromocriptine - a review. Psychopharmacol 95, 433–446CrossRefGoogle ScholarPubMed
Jeste, DVWyatt, RJ (1982) Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry 39, 803–816CrossRefGoogle ScholarPubMed
King, DJ (1990) The effects of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 157, 799–811CrossRefGoogle ScholarPubMed
King, HA (1954) Psychomotor Aspects of Mental Illness. Harvard University Press, CambridgeCrossRefGoogle Scholar
Klonoff, HFibiger, CHHutton, GH (1970) Neuropsychological patterns in chronic schizophrenia. J Nerv Ment Dis 150, 291–300CrossRefGoogle ScholarPubMed
Kornetsky, COrzack, MH (1978) Physiologic and behavioral correlates of attention dysfunction in schizophrenic patients.In: The Nature of Schizophrenia: New Approaches to Research and Treatment (Wynne, LCCromwell, RLMatthysse, S eds).John Wyley, New York, 196–204Google Scholar
Levi-Minzi, SBermanzohn, PCSiris, SG (1991) Bromocriptine for “negative” schizophrenia. Comp Psychiatry 32, 210–216CrossRefGoogle ScholarPubMed
Magliozzi, JRMungas, DLaubly, JNBlinden, D (1989) Effect of haloperidol on a symbol digit substitution task in normal adult males. Neuropsychopharmacol, 2 29–37CrossRefGoogle ScholarPubMed
Medalia, AGold, JMerriam, A (1988) The effects of neuroleptics on neuropsychological tests results of schizophrenics. Arch Clin Neuropsychol 3, 249–271CrossRefGoogle Scholar
Meltzer, HY (1985) Dopamine and negative symptoms in schizophrenia: critique of the type I- II hypothesis.In: Controversies in Schizophrenia (Alpert, M ed). Guilford, New York, 110–136Google Scholar
Merrick, EMSchmitt, PP (1973) A controlled study of the clinical effects of amantadine hypochloride (Symmetrel). Curr Ther Res 15, 552–558Google Scholar
Perovich, RMLieberman, JAFleischhacker, WWAlvir, J (1989) The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 9, 417–422CrossRefGoogle ScholarPubMed
Rosofski, ILevin, SHoltzman, PS (1982) Psychomotility in the funtional psychoses. J Abnorm Psychol 91, 71–74CrossRefGoogle Scholar
Simon-Soret, CBorenstein, Ρ (1987) Essai de la bromocriptine dans le traitemeni de l’autisme infantile. Presse Méd 16, 1286Google Scholar
Steffy, RAGalbraith, KJ (1980) Relation between latency and redundancy-associated deficit in schizophrenic reaction time performance. Abnorm Psychol 89, 419–427CrossRefGoogle ScholarPubMed
Watson, CG (1964) WAIS profile patterns of hospitalized brain-damaged and schizophrenic patients. J Clin Psychol 21, 294–2953.0.CO;2-J>CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.